The clinical efficacy of oral chemoendocrine combination therapy with cyclophosphamide, medroxyprogesterone acetate and doxifluridine (DMpC therapy), was evaluated on advanced and recurrent breast cancer. The response rate was 66.7% in 12 cases, including two complete responses and six partial responses. Restricted to recurrent breast cancer, the response rate was 66.7% that was the same rate of all cases. In terms of the efficacy classified by metastatic lesions, the effective rates were 75% in the skin, 62.5% in the bone, and 75% in the lung. The preoperative reduction therapy was also effective. Adverse side effect was leukopenia in 25% of them that was easily controlled. The response rate was almost the same as that of CAF therapy. On these findings, DMpC therapy is not only the effective therapy, but also the easy and safe oral therapy. In conclusion, DMpC therapy is considered to be one of the most useful treatment for advanced and recurrent breast cancer.